The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
VivianiS., BonadonnaG., SantoroA.Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol.1996; 14(5): 1421–30.
2.
CanellosG.P., AndersonJ.R., PropertK.J.Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med.1992; 327(21): 1478–84.
3.
DeVitaV.T., SerpickA.A., CarboneP.P.Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Int Med.1970; 73(6): 881–95.
4.
BonadonnaG., ZucaliR., MonfardiniS.Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer.1975; 36(1): 252–9.
5.
BonadonnaG., ValagussaP., SantoroA.Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: A report of 8-year results. Ann Int Med.1986; 104(6): 739–46.
6.
SantoroA., BonadonnaG., ValagussaP.Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol.1987; 5(1): 27–37.
7.
GlickJ.H., YoungM.L., HarringtonD.MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial. J Clin Oncol.1998; 16(1): 19–26.
8.
ConnorsJ.M., KlimoP., AdamsG.Treatment of advanced Hodgkin's disease with chemotherapy—comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol.1997; 15(4): 1638–45.
9.
KlimoP., ConnorsJ.MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol.1985; 3(9): 1174–82.
10.
SomersR., CardeP., Henry-AmarM.A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie Controlled Clinical Trial. J Clin Oncol.1994; 12(2): 279–87.
11.
WeinerM.A., LeventhalB.G., MarcusR.Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol.1991; 9(9): 1591–8.
12.
WeinerM.A., LeventhalB., BrecherM.L.Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol.1997; 15(8): 2769–79.
13.
StrausD.J., MyersJ., LeeB.J.Treatment of advanced Hodgkin's disease with chemotherapy and irradiation: Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations. Am J Med.1984; 76(2): 270–8.
14.
StrausD.J., MyersJ., KozinerB.Combination chemotherapy for the treatment of Hodgkin's disease in relapse: Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV). Cancer Chemother Pharmacol.1983; 11(2): 80–5.
15.
StrausD.J.Treatment of advanced Hodgkin's disease. Hematol Oncol Clin North Am.1989; 3(2): 287–302.
TrisselL.A.Handbook on Injectable Drugs.11th ed.Bethesda, MD: ASHP; 2001, 815.
18.
TrisselL.A., ZhangY., CohenM.R.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36(7): 740–5.
19.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–9.
20.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56(8): 729–64.
21.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 2000. Rockledge, PA: National Comprehensive Cancer Network; 2000.
22.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17(9): 2971–94.
SolimandoD.A.Jr, WilsonJ.P.Doxorubicin-induced hypersensitivity reactions. Drug Intelligence Clin Pharm.1984; 18(10): 808–11.
25.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18(20): 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neu-tropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34(12): 1857–64.
28.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony stimulating factors. Curr Opin Hematol.1999; 6(3): 145–51.
29.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care. Eur J Cancer.2000; 36(Suppl 1): S15–21.
30.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–9.
31.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
32.
MullinS.Beckwith MC, Tyler LS. Prevention and management of anti-neoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
33.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: PerryM.C., Ed. The Chemotherapy Source Book.2nd ed.Baltimore, MD: Williams and Wilkins; 1996, 727–44.
34.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
35.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24(4): 969–90.
36.
HaimN., EpelbaumR., Ben-ShaharM.Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer.1994; 73(10): 2515–9.
